Conversation
Friend wrote.
$SAVA and $AVXL just released clinical trial data, showing the first ever (as far as I know) treatment that *improves* cognitive function in patients with Alzheimers, with no reported side effects. Their huge burst is driven by data from clinical trials $AVXL hasn’t released any AD data (recently). $sava has (open-label). $AVXL going much higher. They are actually well ahead of $SAVA Yes they are already in phase 3, but I don’t think they had a promising phase 2 like what $SAVA had. You’re unable to view this Tweet because this account owner limits who can view their Tweets. Learn more $SAVA had great phase 2 data. If their phase 3 is successful, it will be the first Alzheimer’s drug in the market. $$ potential is huge. That’s why the crazy run up. That said, treating a neurological disease is complex and not one company has been successful with Alzheimer’s Check out $KMPH... it's the next $SAVA. ADHD Drug will be approved Mar 2nd... debt free, $55m in cash and another $48m coming, Only has a 4m float. This is a billion dollar drug approval. 
